Tobias Madl, PhD
Medical University
Biography & Research Background
Tobias Madl, PhD, is a structural biologist at the Medical University of Graz (Institute of Molecular Biology & Biochemistry, Center of Molecular Medicine) and co-founder of Cleara Biotech B.V. He is a leader in NMR spectroscopy who played a key role in the drug design platform for FOXO4-DRI. His structural work characterized the interaction domain between FOXOs and p53, confirming that FOXO4-DRI competes with endogenous FOXO4 for p53 binding. In 2025, his team solved the solution NMR structure of the p53 transactivation domain in complex with FOXO4-DRI, identifying p53 TAD2 as the specific binding site and revealing that phosphorylation of p53 at Ser46 and Thr55 significantly enhances binding affinity. His key publications include "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging" (2017, Cell), "Regulation of cellular senescence via the FOXO4-p53 axis" (2018, FEBS Letters), and "The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI" (2025, Nature Communications). Tobias Madl is being referenced as one of the leading scientists involved in FOXO4-DRI research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Tobias Madl, PhD is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Tobias Madl, PhD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.